2-(5-nitro-3-phenylsulfanyl-6-trifluoromethyl-1H-indol-2-yl)-propan-2-ol

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(5-nitro-3-phenylsulfanyl-6-trifluoromethyl-1H-indol-2-yl)-propan-2-ol
• 英文别名: 2-[5-nitro-3-phenylsulfanyl-6-(trifluoromethyl)-1H-indol-2-yl]propan-2-ol
• 化学式: C₁₈H₁₅F₃N₂O₃S
• 分子量: 396.39
• InChiKey: YLCIKKVWRRVNMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-(5-nitro-6-trifluoromethyl-1H-indol-2-yl)-propan-2-ol 、 二苯二硫醚 以 N,N-二甲基甲酰胺 为溶剂， 反应 64.0h， 以10%的产率得到2-(5-nitro-3-phenylsulfanyl-6-trifluoromethyl-1H-indol-2-yl)-propan-2-ol
  参考文献：
  名称：

  WO2006/49889

  摘要：

  公开号：

文献信息

• Indole derivatives useful as progesterone receptor modulators
  申请人：Jiang Weiqin

  公开号：US20060111427A1

  公开（公告）日：2006-05-25

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.

  本发明涉及新型吲哚衍生物、含有它们的制药组合物及其在治疗或预防由孕激素受体激动剂和拮抗剂介导的疾病和疾病中的应用。这些化合物的临床用途与避孕、治疗和/或预防继发性闭经、功能性出血、子宫肌瘤、子宫内膜异位症、多囊卵巢综合征、子宫内膜癌和腺癌、卵巢、乳房、结肠、前列腺癌或减少周期性月经出血的副作用有关。本发明的其他用途包括促进食物摄入。
• INDOLE DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS
  申请人：Jiang Weiqin

  公开号：US20070135511A1

  公开（公告）日：2007-06-14

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.

  本发明涉及新型吲哚衍生物、含有它们的制药组合物以及它们在治疗或预防由孕激素受体激动剂和拮抗剂介导的疾病和疾病中的应用。这些化合物的临床用途涉及避孕、治疗和/或预防继发性闭经、功能性出血、子宫平滑肌瘤、子宫内膜异位症、多囊卵巢综合症、子宫内膜癌和腺癌、卵巢、乳房、结肠、前列腺癌或减少月经出血的副作用。本发明的其他用途包括促进食物摄入。
• US7183309B2
  申请人：——

  公开号：US7183309B2

  公开（公告）日：2007-02-27
• US7345084B2
  申请人：——

  公开号：US7345084B2

  公开（公告）日：2008-03-18
• [EN] INDOLE DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS<br/>[FR] DERIVES D'INDOLE UTILES EN TANT QUE MODULATEURS RECEPTEURS DE PROGESTERONE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006049889A1

  公开（公告）日：2006-05-11

  [EN] The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.
  [FR] L'invention concerne de nouveaux dérivés d'indole, des compositions pharmaceutiques les contenant et leur utilisation dans le traitement ou la prévention de troubles ou de maladies induites par des agonistes et des antagonistes du récepteur de progestérone. Les utilisations cliniques de ces composés sont en rapport avec la contraception, le traitement et/ou la prévention de l'aménorrhée secondaire, la ménométroragie, la léiomyomatose utérine, l'endométriose utérine, le syndrome de Stein-Leventhal, les carcinomes et les adénocarcinomes de l'endomètre, des ovaires, de la poitrine, du colon, de la prostate, ou la réduction des effets secondaires des saignements du cycle menstruel. Parmi d'autres utilisations de l'invention, on peut citer la stimulation d'ingestion d'aliments.